Key result
This editorial highlights recent advances in heart failure treatment, reviewing studies on sacubitril/valsartan, nitrates-hydralazine, CHA2DS2-VASc scores, lead extractions, and Mitraclip therapy.
Answers are grounded in this paper and cite their sources.
This editorial provides an overview of key heart failure research published in the October 2016 issue, highlighting advances in medical therapy, risk stratification, and device management.
The current issue is focused on treatment of heart failure (HF), a field where major advances have recently occurred. The Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial is a landmark study for HF treatment, going to change clinical practice in the next years.1, 2 In this issue of our journal, Milton Packer reviews the possible causes of the relatively slow uptake of sacubitril/valsartan in clinical practice in the United States and further shows the strength of this trial with new analyses.3 Vardeny et al. have analysed the patients who had a dose reduction of the study drug in PARADIGM-HF.4 This event occurred in 42% of the patients on sacubitril/valsartan and 43% of those on enalapril. Any dose reduction was associated with a 2.5-fold higher risk of the primary event. However, the treatment benefit of sacubitril/valsartan versus enalapril was of similar magnitude in the patients who had experienced a dose reduction, compared with the others.4 Lastly, Solomon et al. have performed a meta-analysis of the three trials that have compared a neprilysin/renin–angiotensin system (RAS) inhibitor with a RAS inhibitor in patients with HF and reduced ejection fraction (HFrEF) showing consistency of the results across the trials analysed.5 The Bi treatment with hydralazine/nitrates versus placebo in Africans admitted with acute HEart Failure (BA-HEF) was a prospective, multicentre, randomized, double-blind, placebo controlled, trial to assess the efficacy of nitrates–hydralazine combination in patients recently admitted for acute HF in sub-Saharan Africa.6 The trial was stopped prematurely for difficulties in enrolment with no differences in the primary endpoint and trends in favour of the active treatment. As pointed out by Marriel Jessup in her editorial comment, BA-HEF can be seen as a trial targeted at a specific patients' group and should be followed by further studies with better patients' genotyping at baseline. As modern humans have evolved from archaic ones located in eastern Africa, Africa can be seen as “the most logical place to begin a more genomic approach to human HF.”7 Ye et al. have examined the prognostic significance of the CHA2DS2-VASc score in the patients with HFrEF and sinus rhythm enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. Each 1-point increase in the CHA2DS2-VASc score was associated with a 21% increase in the hazard of death or ischaemic stroke both in patients on warfarin and in those on aspirin. Similar results were found for death alone, ischaemic stroke alone, and major haemorrhage.8 These results are consistent with those of a recent large registry from Denmark showing an increase in the risk of thromboembolic events with higher CHA2DS2-VASc scores, in 136 545 patients admitted with HF in sinus rhythm.9 These results are the rationale behind ongoing trials of non-vitamin K antagonist oral anticoagulants in patients with HF and sinus rhythm.10 Regoli et al. report the results and adverse events of transvenous lead extractions (TLE) performed in 256 consecutive patients with HFrEF and cardiac resynchronization therapy. TLE was performed for systemic (18%) or local (45%) infections, system malfunction (34%), or other causes (3%). The procedure was successful in 99.2% of the cases. However, during a median follow-up of 21 months, there was a high rate of adverse events (AEs) or system-related AEs (53.9% and 21.1%, respectively) including recurring system malfunction (9.0%), infection (6.2%), and pocket haematoma requiring revision (5.9%). Oral anticoagulation therapy was an independent predictor of AEs.11 There is limited evidence regarding the feasibility of Mitraclip therapy in patients with missing leaflet coaptation (MLC). Adamo et al. have compared Mitraclip therapy in 22 consecutive patients with MLC versus 40 other patients without MLC. Both groups had functional mitral regurgitation and similar baseline clinical characteristics. Short- and long-term procedural success were similar between the patients with and without MLC. Mitral regurgitation, estimated pulmonary artery systolic pressure and the New York Heart Association functional class improved but left ventricular dimensions did not change in both these high risk groups. During a median follow-up of 360 days, cardiovascular death or HF hospitalizations rates were high in both cases (49.9% and 44.4%).12 Prediction of myocardial recovery during mechanical circulatory support is a major need. In this issue of the journal, Chaggar et al. review the topic.13 The incidence of full recovery, post-explant outcomes, clinical and biochemical predictors of recovery, genomic and transcriptomics control mechanisms are described.14 Better patients' characterization is still an unmet clinical need in HF patients. Few data have been obtained and were mainly based on demographic characteristics and traditional clinical and laboratory parameters.15-18 This issue is concluded by the design of an epidemiological study, the Preserved and Reduced Ejection Fraction Epidemiological Regional Study (PREFERS), to be conducted in Stockholm, Sweden. PREFERS is designed to enrol 2000 patients with new-onset HF who will be evaluated at baseline and after 1-year follow-up by clinical assessment, ECG, echocardiography and blood sampling. One subset of 100 patients undergoing elective coronary bypass surgery will also undergo myocardial biopsy and cardiac magnetic resonance imaging. The aim is to identify new biomarkers of disease progression and of pathophysiological mechanisms that can better characterize and compare patients with new-onset HF, with a reduced or preserved ejection fraction, and find novel therapeutic targets.19
No takes yet. Share an insight, caveat, or question.
Marco Metra (2016) conducted an editorial in Heart failure. This editorial highlights recent advances in heart failure treatment, reviewing studies on sacubitril/valsartan, nitrates-hydralazine, CHA2DS2-VASc scores, lead extractions, and Mitraclip therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: